ARTICLE | Finance
Icahn's Squibb kick
Carl Icahn needs bigger bid for Amylin than purported $22 from Bristol-Myers
April 9, 2012 7:00 AM UTC
If Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) did in fact reject a takeover bid from Bristol-Myers Squibb Co. (NYSE:BMY) in February, Carl Icahn says the biotech ought to have disclosed it to shareholders. But that does not mean he wanted the BMS deal, as the $22 per share offer price would leave him under water.
The activist investor reported in an SEC filing last week that he bought his 14.4 million shares, representing 8.9% of Amylin, for an average price of $23.30. He first disclosed a stake in the diabetes company four years ago...